HUE053557T2 - Eljárások akut vesekárosodás kezelésére - Google Patents

Eljárások akut vesekárosodás kezelésére

Info

Publication number
HUE053557T2
HUE053557T2 HUE17787773A HUE17787773A HUE053557T2 HU E053557 T2 HUE053557 T2 HU E053557T2 HU E17787773 A HUE17787773 A HU E17787773A HU E17787773 A HUE17787773 A HU E17787773A HU E053557 T2 HUE053557 T2 HU E053557T2
Authority
HU
Hungary
Prior art keywords
procedures
acute renal
treating acute
renal impairment
impairment
Prior art date
Application number
HUE17787773A
Other languages
English (en)
Hungarian (hu)
Inventor
Bharat Lagu
Michael Patane
Effie Tozzo
Scott Trzaska
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of HUE053557T2 publication Critical patent/HUE053557T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE17787773A 2016-10-05 2017-10-05 Eljárások akut vesekárosodás kezelésére HUE053557T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05

Publications (1)

Publication Number Publication Date
HUE053557T2 true HUE053557T2 (hu) 2021-07-28

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17787773A HUE053557T2 (hu) 2016-10-05 2017-10-05 Eljárások akut vesekárosodás kezelésére

Country Status (33)

Country Link
US (1) US20210283116A1 (enExample)
EP (1) EP3522880B1 (enExample)
JP (1) JP7065839B2 (enExample)
KR (1) KR20190062502A (enExample)
CN (1) CN109789117B (enExample)
AU (1) AU2017340760B2 (enExample)
BR (1) BR112019005539A2 (enExample)
CA (1) CA3036723A1 (enExample)
CO (1) CO2019004561A2 (enExample)
CY (1) CY1124759T1 (enExample)
DK (1) DK3522880T3 (enExample)
ES (1) ES2859487T3 (enExample)
HR (1) HRP20210294T1 (enExample)
HU (1) HUE053557T2 (enExample)
IL (1) IL265749A (enExample)
JO (1) JOP20190056B1 (enExample)
LT (1) LT3522880T (enExample)
MA (1) MA46459B1 (enExample)
MD (1) MD3522880T2 (enExample)
MX (1) MX387518B (enExample)
MY (1) MY192385A (enExample)
PH (1) PH12019500725A1 (enExample)
PL (1) PL3522880T3 (enExample)
PT (1) PT3522880T (enExample)
RS (1) RS61573B1 (enExample)
RU (1) RU2753607C2 (enExample)
SG (1) SG11201901925RA (enExample)
SI (1) SI3522880T1 (enExample)
SM (1) SMT202100111T1 (enExample)
TW (1) TWI778982B (enExample)
UA (1) UA124019C2 (enExample)
WO (1) WO2018067857A1 (enExample)
ZA (1) ZA201901743B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122237C2 (uk) 2015-10-07 2020-10-12 Мітобрідж, Інк. Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування
MX380531B (es) * 2016-04-13 2025-03-12 Mitobridge Inc Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
ES2887008T3 (es) 2016-10-05 2021-12-21 Mitobridge Inc Formas cristalinas y de sal de compuestos agonistas del PPAR
EP3999060A1 (en) 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
EP4305024A1 (en) * 2021-03-08 2024-01-17 Abionyx Pharma SA Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414534B8 (pt) * 2003-09-19 2021-05-25 Janssen Pharmaceutica Nv ácidos 4-((fenoxialquila)tio)-fenoxiacéticos e análogos e composição farmacêutica compreendendo-os
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20110091680A (ko) * 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ldl 입자를 감소시키는 방법
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury
EP2981522A4 (en) * 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
EP2862574A1 (en) * 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
CN105917229B (zh) * 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
UA122237C2 (uk) * 2015-10-07 2020-10-12 Мітобрідж, Інк. Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування

Also Published As

Publication number Publication date
MX2019003949A (es) 2019-06-10
LT3522880T (lt) 2021-03-25
CY1124759T1 (el) 2022-07-22
US20210283116A1 (en) 2021-09-16
RU2753607C2 (ru) 2021-08-18
PH12019500725A1 (en) 2019-08-05
MA46459A (fr) 2019-08-14
JOP20190056A1 (ar) 2019-03-24
WO2018067857A1 (en) 2018-04-12
MY192385A (en) 2022-08-18
SMT202100111T1 (it) 2021-05-07
SG11201901925RA (en) 2019-04-29
IL265749A (en) 2019-06-30
RS61573B1 (sr) 2021-04-29
MX387518B (es) 2025-03-18
CA3036723A1 (en) 2018-04-12
KR20190062502A (ko) 2019-06-05
MD3522880T2 (ro) 2021-03-31
AU2017340760B2 (en) 2023-07-27
CN109789117B (zh) 2022-08-23
TWI778982B (zh) 2022-10-01
HRP20210294T1 (hr) 2021-04-16
ZA201901743B (en) 2022-04-28
TW201815391A (zh) 2018-05-01
EP3522880A1 (en) 2019-08-14
AU2017340760A1 (en) 2019-03-21
JP2019533660A (ja) 2019-11-21
BR112019005539A2 (pt) 2019-06-18
EP3522880B1 (en) 2020-12-02
DK3522880T3 (en) 2021-01-18
RU2019111421A (ru) 2020-11-06
CN109789117A (zh) 2019-05-21
SI3522880T1 (sl) 2021-07-30
PL3522880T3 (pl) 2021-08-23
ES2859487T3 (es) 2021-10-04
JP7065839B2 (ja) 2022-05-12
PT3522880T (pt) 2021-02-22
JOP20190056B1 (ar) 2022-03-14
MA46459B1 (fr) 2021-03-31
UA124019C2 (uk) 2021-07-07
RU2019111421A3 (enExample) 2021-02-05
CO2019004561A2 (es) 2019-07-31

Similar Documents

Publication Publication Date Title
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
IL257252A (en) Methods of treating fgf21-associated disorders
MA45277A (fr) Promédicaments de pth
HUE053557T2 (hu) Eljárások akut vesekárosodás kezelésére
IL264451A (en) Combination treatment for hematological cancers
PL3386655T3 (pl) Sposób przetwarzania odpadów
PT3265087T (pt) Método de tratamento com tradipitant
EP3551270A4 (en) FILTER ASSEMBLY
DE112017004700B8 (de) Shift-by-Wire-System
DK3294769T3 (da) Behandling for multipelt myelom (mm)
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
DK3286260T3 (da) Polyolefinrør
EP3512340A4 (en) BALLAST WATER MANAGEMENT SYSTEM
IL261121A (en) A system for performing spectroscopy
EP3329635A4 (en) FORGERY PROTECTION
IL257596A (en) Methods for treatment of polycystic kidney disease
EP3812637C0 (de) Spannschelle
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
DK3305977T3 (da) Automatisk stoftilfører
DK3380983T3 (da) Fremgangsmåde til identifikation af sikkerhedsprocessorer
ES1157711Y (es) Filtro
IL270867A (en) Treatment method
EP3615175C0 (en) FILTER SYSTEM
EP3393266C0 (en) MULTILAYER FILTRATION DEVICE
FI20155671A7 (fi) Menetelmä veden käsittelemiseksi